Credit Suisse Ag Palatin Technologies Inc Transaction History

Credit Suisse Ag

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 13, 2020	SELL	$0.36 - $0.79 $6,185 - $13,572	-17,181 Closed	0 $0
Q4 2019 Feb 12, 2020	SELL	$0.75 - $0.89 $23,699 - $28,123	-31,599 Reduced 64.78%	17,181 $13,000
Q3 2019 Nov 12, 2019	BUY	$0.78 - $1.09 $8,982 - $12,552	11,516 Added 30.9%	48,780 $44,000
Q2 2019 Aug 14, 2019	SELL	$0.98 - $1.64 $10,829 - $18,123	-11,051 Reduced 22.87%	37,264 $43,000
Q1 2019 May 14, 2019	BUY	$0.67 - $1.01 $7,744 - $11,674	11,559 Added 31.45%	48,315 $47,000
Q4 2018 Feb 13, 2019	BUY	$0.63 - $1.0 $16,169 - $25,666	25,666 Added 231.43%	36,756 $26,000
Q3 2018 Nov 13, 2018	SELL	$0.88 - $1.1 $36,591 - $45,739	-41,581 Reduced 78.94%	11,090 $11,000
Q2 2018 Aug 14, 2018	BUY	$0.91 - $1.45 $47,930 - $76,372	52,671 New	52,671 $51,000

2.94K

Ticker PTN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 9,290,480
Market Cap $10.8M
Description
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing o...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.